The HER family as therapeutic targets in colorectal cancer - ScienceDirect
Tucatinib Approved for HER2-Positive Colorectal Cancer - NCI
Q&A column - CAP TODAY
IJMS | Free Full-Text | Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer
Frontiers | Remarkable Response of EGFR- and HER2-Amplified Metastatic Colon Cancer to Pyrotinib After Failed Multiline Treatments: A Case Report and Literature Review
![HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]](https://dfzljdn9uc3pi.cloudfront.net/2020/8602/1/fig-5-2x.jpg "HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]")
HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]
Anti-HER2 Agents Gain Ground in Colorectal Cancer
HER2 Biomarker | Colorectal Cancer Alliance
The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review - ScienceDirect
HER2 G776S mutation promotes oncogenic potential in colorectal cancer cells when accompanied by loss of APC function | Scientific Reports
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study | Modern Pathology
Precision Cancer Medicines for Colon Cancer - CancerConnect
Dual HER2 Blockade in Patients With HER2-Amplified Metastatic
A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway | Cell Death & Disease
HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target | American Society of Clinical Oncology Educational Book
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study - The Lancet Oncology
HER2 Status in Colorectal Cancer: Its Clinical Significance and the Relationship between HER2 Gene Amplification and Expression | PLOS ONE
Dual HER2 Blockade in Patients With HER2-Amplified Metastatic
Frontiers | Human Epidermal Growth Factor Receptor 2 Overexpression and Amplification in Patients With Colorectal Cancer: A Large-Scale Retrospective Study in Chinese Population
IJMS | Free Full-Text | Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer - ScienceDirect
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer
HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti‐Epidermal Growth Factor Receptor Therapy | Semantic Scholar
